16 September 2026 editorial review · Trial
Open-source artificial pancreas use in China: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Replaced vagueeligibility; flagged header3–75 vsprose allages discrepancy ratherthan guessing.
Registry: NCT06081231. Endpoint reviewed: proportion of time spent in the target glucose range (baseline(at least 2 weeks before the start of APS), and 3 months,6 months, 9 months, 12 months, and following period after the start of APS). Eligibility reviewed: Age 3 Years to 75 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.